In this review:
Curative strategy for high-risk smouldering MM
Busulfan plus melphalan vs melphalan alone for MM
Daratumumab bortezomib, melphalan, and prednisone in NDMM
Anti-BCMA CAR-T cell therapy
Antibody drug conjugate against BCMA
Minimal residual disease in MM
Daratumumab, carfilzomib, lenalidomide, dexamethasone in NDMM
Lenalidomide in ASCT eligible and ineligible patients
Response-adapted lenalidomide maintenance in transplant-eligible MM
Ixazomib/thalidomide/low dose dexamethasone in ASCT ineligible NDMM
Please login below to download this issue (PDF)